Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14764522 | 0.82 | ALDH1A1 (0.54) | PIK3CGALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL12502826 | 0.82 | ALDH1A1 (0.54) | PIK3CGALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL437073 | 0.82 | NQO2 (0.48) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL23234459 | 0.82 | HTT (0.43) | ALDH1A1KDM4EMEN1KMT2AGAA | |
| SCHEMBL10846446 | 0.82 | RXFP1 (0.45) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL10846397 | 0.80 | PGK1 (0.44) | PIM1PGK1DYRK1A | |
| SCHEMBL462643 | 0.80 | TDP1 (0.58) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL404069 | 0.80 | TDP1 (0.55) | PIK3CGALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL29581162 | 0.80 | TDP1 (0.55) | PIK3CGALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL7350739 | 0.78 | HRH4 (0.50) | PIK3CGALDH1A1MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011112731-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2324029-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-5559106-A | Heterocyclic compounds, their use and preparation | NOVO NORDISK A/S (DK) | 1996-09-24 | — | — | US | disclosed |
| US-5504085-A | TREATING ISCHEMIA, ANOXIA, HYPOGLYCEMIA AND HEAD, SPINAL CORD TRAUMA | NOVO NORDISK A/S (DK) | 1996-04-02 | — | — | US | disclosed |
| US-4623725-A | [1,2,4]Triazolo[4,3-a]quinoxaline-4-amine derivatives | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0107455-B1 | TRIAZOLOQUINOXALINES AS ANTIDEPRESSANTS AND ANTIFATIGUE AGENTS | PFIZER INC. (US) | 1986-07-09 | — | — | EP | disclosed |
| US-4547501-A | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | PFIZER INC. (US) | 1985-10-15 | — | — | US | disclosed |
| US-4495187-A | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | PFIZER INC. (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0107455-A1 | Triazoloquinoxalines as antidepressants and antifatigue agents | PFIZER INC. (US) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | PIK3CG 4151/4885ALDH1A1 1909/4885MAPT 2336/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | PIK3CG 4151/4885ALDH1A1 1909/4885MAPT 2336/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | PIK3CG 4151/4885ALDH1A1 1909/4885MAPT 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.